Citigroup has downgraded Qiagen NV (QGEN) to Neutral from Buy, effective December 10, 2025. The stock currently trades at $45.29.
This move underscores a shift in sentiment regarding Qiagen's outlook, potentially reflecting concerns over competitive pressures, market conditions, or execution risks that could affect the company's performance.
Qiagen, headquartered in Venlo, Limburg, specializes in Sample to Insight solutions, enabling customers to extract molecular insights from biological samples. The company has a market capitalization of $9.9 billion and a trailing P/E ratio of 24.37. Its earnings per share (EPS) for the trailing twelve months stands at 1.84, with a notable dividend yield of 54.5%.
Upcoming earnings reports are scheduled for August 3, 2026, with an estimated EPS of $0.66 and revenue of $569.5 million. Analysts currently maintain a consensus rating of Buy, with 5 Strong Buy, 7 Buy, 12 Hold, and no Sell or Strong Sell ratings among 24 total analysts.
Analyst ratings are based on research and financial models, providing a professional perspective that should be considered alongside company fundamentals, competitive positioning, and industry trends. As market conditions evolve, so too may analyst opinions on Qiagen NV.